Research and Markets: Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/8f18b5/delivering_rnaiba) has
announced the addition of the "Delivering RNAi-Based Therapeutics & Diagnostics:
Challenges & Opportunities" report to their offering.

This cutting edge & insightful report can be used to interpret & assess the
potential of RNAi-based medicines. It provides opinions & market projections
to:

* assess the commercial potential of RNAi-based therapies in all of the key
therapeutic areas: cancer, CNS disorders, viral infectious diseases, ocular
diseases, cardiovascular, metabolic and other conditions;
* identify key pharma & delivery specialists advancing RNAi-based therapeutics &
diagnostics;
* gain an in-depth understanding of the technological & delivery issues which
face companies developing RNAi-based therapies;
* evaluate the options available for chemically and structurally modifying RNAi
silencing agents and delivering them to target tissues now & in the future;
* discover which companies are tackling efficacy and safety issues & are in a
prime position to exploit new opportunities;
* analyze how the market will evolve over the next decade highlighting key
trends, opportunities & challenges.

SOME KEY FINDINGS:

* Since the 1990s scientists across the world have begun to harness the power of
RNA interference (RNAi) to silence genes in a multitude of diseases. However,
many challenges face those aiming to develop RNAi-based therapies including
targeted delivery, the design and efficacy of gene silencing agents and the
minimization of off-target and immunogenic effects.
* Today there are over 100 RNAi-based projects under investigation to treat
autoimmune and inflammatory diseases, cancer, cardiovascular disease, CNS
disorders, metabolic, ocular conditions, and viral infectious diseases. The
majority of these projects are in the earliest discovery stages (36%) or in
preclinical studies (54%). Of the projects that have reached clinical trials,
only a handful have passed initial Phase 1/2 testing, with a total of three
being investigated in Phase 2 studies.
* In 1H09 two late-stage ocular RNAi-based therapies, Opko Health's bevasiranib
and Allergan's AGN-745, were terminated in late-stage clinical trials after the
drugs failed to meet a key efficacy endpoint. This is a major set back for
market and raises questions regarding the potential of unformulated siRNAs as
therapeutics.
* Despite these challenges and others, such as the complexities of regulation
and intellectual property, the field retains enormous potential to diagnose and
treat diseases with high unmet medical need. Specialists and academics are
working hard to find ways around these hurdles in order to deliver a new
generation of RNAi-based therapeutics and diagnostics.
* The market for RNAi-based therapeutics is forecast to grow from 2013 onwards,
as the first products enter the marketplace, to generate sales in excess of
US$2.9 billion by 2020. The first siRNA based therapeutics will capitalize on
the demand to treat viral infections and ocular conditions and in the longer
term companies will be able to target niche areas of high unmet clinical need
such as cancer, cardiovascular disease, metabolic disorders, inflammatory and
neurological conditions.

Key Topics Covered:

Chapter 1 Rna Interference & Delivery

Chapter 2 Rnai-Based Therapeutics: Pipeline Analysis

Chapter 3 Rnai-Based Therapies For Cancer

Chapter 4 Rnai-Based Therapies For Cns Disorders

Chapter 5 Rnai-Based Therapies For Viral Infectious Diseases

Chapter 6 Rnai-Based Therapies For Ocular Diseases

Chapter 7 Rnai-Based Therapies For Cardiovascular, Metabolic & Other Conditions

Chapter 8 Challenges & Opportunities For Rnai-Based Therapeutics & Diagnostics

Chapter 9 The Future Of Rnai-Based Therapeutics & Diagnostics: Market Trends

Companies Mentioned:

RNAi therapeutic companies:

* AiRNA Pharmaceuticals
* Allergan
* Alnylam
* Pharmaceuticals
* Benitec
* BioCandell Therapeutics
* Calando
* Pharmaceuticals
* Cenix BioScience
* Cequent Pharmaceuticals
* Copernicus
* Therapeutics
* Dicerna Pharmaceuticals
* Expression Genetics Corporation,
* General Research Laboratory
* Intradigm Corporation
* MDRNA
* Mirna
* Therapeutics
* MiRagen Therapeutics
* Nitto Denko Technical Corporation,
* Opko Health
* Oxford BioMedica
* Polyplus Transfection
* Quark
* Pharmaceuticals
* Regulus Therapeutics
* RXi Therapeutics
* Santaris
* Pharma
* Senesco Technologies
* Silence Therapeutics
* Siranoamics,
* siRNAsense A/S
* Sylentis Pharmaceuticals
* Tacere Therapeutics
* Targeted
* Genetics Corporation
* Tekmira Pharmaceuticals Corporation.

Antisense therapeutic companies:

* Isis Pharmaceuticals
* Lorus
* Therapeutics & Santaris Pharma.

Pharmaceuticals & biotechnology companies:

* AstraZeneca
* Bristol-
* Myers Squibb
* Biogen Idec
* Cubist Pharmaceuticals
* Eli Lilly
* Enzon,
* Genzyme
* Kyowa Hakko Kirin
* Merck & Co.
* Novartis
* Oncolys BioPharma,
* Pfizer
* Roche & Takeda.

RNAi diagnostic companies:

* Asuragen Diagnostics
* Exiqon Diagnostics
* Rosetta Genomics

For more information visit
http://www.researchandmarkets.com/research/8f18b5/delivering_rnaiba

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009